Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients. Dr Richard Knight of Alderley Park-based ApconiX told last month’s conference, Accelerating Cancer Drug Development – from target to patients, that greater focus on pre-clinical safety should be fundamental to [...]

By |2018-07-11T10:12:48+00:00March 27th, 2018|Toxicology|Comments Off on Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”